Four questions on new safety warnings for Neurocrine’s Vykat XR
Four questions on new safety warnings for Neurocrine’s Vykat XR
Neurocrine Biosciences
Neurocrine Biosciences is a late-stage neuroscience biotech commercializing treatments for movement disorders, neuropsychiatry, and rare neurological conditions, including Ingrezza (valbenazine) and Vykat XR for Prader-Willi syndrome.
Company Info
Recent News
Neurocrine stands by blockbuster hopeful Vykat XR as Prader-Willi docs raise potential safety flags
Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to the Prader-Willi syndrome (PWS) community is flagging potential safety concerns about the rare dise | Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to the Prader-Willi syndrome (PWS) community is flagging potential safety concerns about the rare-disease med, acquired in Neurocrine’s $2.9 billion buyout of Soleno Therapeutics last spring.
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug